Two days ago, on November 3, 2026, 3M Company signed and filed a landmark Master Settlement Agreement with the U.S. Securities and Exchange Commission — an event that reshapes the entire landscape of the AFFF lawsuit settlement 2026 and marks the single most consequential development in the eight-year history of In re Aqueous Film-Forming Foams Products Liability Litigation (MDL 2873). If you or a family member has been diagnosed with kidney cancer, testicular cancer, liver cancer, thyroid cancer, thyroid disease, or ulcerative colitis after exposure to AFFF firefighting foam, you need to understand what this agreement means — and why a court-ordered deadline of November 13, 2026 makes the next ten days critical.
What 3M’s Master Settlement Agreement Actually Says
The agreement — disclosed via a 3M Form 8-K and an accompanying press release on November 3, 2026 — resolves approximately 99% of all current personal injury claims filed both inside and outside MDL 2873, covering an estimated 115,000 to 120,000 eligible claimants. The total settlement value is $7.35 billion nominal, structured across nine years of payments from 2026 through 2034. Because most of that money arrives in later years, 3M disclosed a present value of $5.8 billion — a figure the company will record as a pre-tax charge in Q4 2026. For context, as of October 1, 2026, the JPML reported 15,264 pending cases inside the MDL alone, underscoring the sheer scale of this resolution.
The payment schedule is deliberately back-loaded. A modest $50 million payment is due in 2026, with no payments scheduled for 2027. The bulk of the fund — approximately $6.27 billion — flows in annual installments from 2028 through 2033, after participation thresholds are certified. A separate $680 million reserve fund has been carved out specifically to manage remaining and future personal injury claims that fall outside the primary settlement pool, both inside and outside the MDL. This reserve signals that 3M and plaintiffs’ leadership expect some volume of claims to persist beyond the current enrollment window.
Critically, this is an opt-in settlement. Participation is not automatic. Each claimant must affirmatively enroll and provide 3M a full release of all PFAS-related personal injury claims. 3M does not admit liability or wrongdoing under the agreement. Participation thresholds remain sealed, but 3M retains a walk-away right exercisable within 45 days of receiving final participation numbers — a provision that makes claimant enrollment rates an existential variable for the entire deal. The measurement window for enrollment runs until December 15, 2029 at the latest.
The November 13 Deadline You Cannot Miss
Judge Richard Gergel of the U.S. District Court for the District of South Carolina issued Case Management Order 39 (CMO 39), which establishes November 13, 2026 as the claimant-identification deadline. By that date, eligible claimants must be formally identified to the court. Cases filed after November 13 carry an additional requirement: counsel must include a certification documenting when the client was retained. This procedural distinction matters because it may affect a late-filing claimant’s position within the enrollment and distribution process. For unrepresented individuals who have received one of the six qualifying diagnoses, acting before this deadline — or understanding its implications immediately afterward — is not optional. The CDC’s PFAS health information hub provides background on exposure pathways for those assessing whether they qualify.
Statutes of limitations for toxic tort and personal injury claims vary by state — typically running two to three years from diagnosis or discovery under the discovery rule — meaning some individuals exposed decades ago may still have actionable claims if their diagnosis is recent. If you are evaluating what a potential claim could be worth before retaining counsel, a personal injury settlement calculator can help you model general compensation ranges based on injury type, severity, and economic losses. That said, mass tort settlements distribute funds according to case-specific point systems, so individual results will depend heavily on your diagnosis category and exposure history.
Who Is Eligible: Six Qualifying Diagnoses and Primary Plaintiff Groups
The Master Settlement Agreement identifies six qualifying cancer and disease categories for claimant eligibility. Understanding whether your diagnosis falls within these categories is the threshold question every potential claimant must answer before the enrollment window opens.
| Qualifying Diagnosis | Category Type | Notes |
|---|---|---|
| Kidney Cancer | Malignancy | Among the most studied PFAS-associated cancers |
| Testicular Cancer | Malignancy | Elevated incidence documented in PFAS-exposed populations |
| Liver Cancer | Malignancy | Linked to PFOA/PFOS exposure in epidemiological studies |
| Thyroid Cancer | Malignancy | Covered under both cancer and disease tracks |
| Thyroid Disease | Non-malignant Disease | Includes hypothyroidism and related conditions |
| Ulcerative Colitis | Non-malignant Disease | Inflammatory bowel condition associated with PFAS exposure |
The primary plaintiff groups in the AFFF lawsuit settlement 2026 include military veterans, military and civilian firefighters, airport workers, fire training site personnel, and individuals who lived near contaminated military bases or airports and consumed PFAS-polluted drinking water. The CDC/ATSDR is actively conducting exposure assessments at communities near military installations — assessments that may help claimants document their exposure histories. The military historically accounted for an estimated 75% of all AFFF use, and AFFF has been deployed at military bases, commercial airports, and fire training sites since the 1960s. PFAS chemicals from foam use seeped into groundwater and reached drinking water supplies at hundreds of sites nationwide. The International Agency for Research on Cancer has identified firefighters as having particularly high exposure to PFAS from foam use.
In cases where AFFF exposure ultimately proves fatal — particularly for claimants who have passed away before or during the litigation — surviving family members may have separate wrongful death claims. Using a wrongful death calculator can help families understand the economic loss components typically factored into such claims, including lost future earnings, loss of consortium, and funeral expenses, before consulting with legal counsel about their specific options.
What Is NOT Resolved: DuPont, the Water-System Track, and MDL 3191
It is essential to understand three things the AFFF lawsuit settlement 2026 does not cover, because confusion among these tracks is widespread and legally consequential.
First, DuPont has not settled. As of September 30, 2026, DuPont reported approximately 13,700 personal injury cases pending in MDL 2873 and continues mediation talks. DuPont claimants are not covered by the 3M agreement and face a separate, unresolved litigation path. Second, the 3M personal injury deal is entirely separate from the previously resolved public-water-system track, in which 3M reached a $10.5–$12.5 billion nominal water-system settlement that received final judicial approval on March 29, 2024. Personal injury claimants and water-system claimants are distinct categories and the settlements operate independently. Third, MDL 3191 — the Non-AFFF Firefighter Turnout Gear MDL created in August 2026 — involves an entirely different court, a different defendant set, and different product-liability claims. Cornell Law’s MDL explainer provides helpful background on how these consolidated proceedings are structured for those unfamiliar with federal multidistrict litigation.
The two principal negotiators who brokered the 3M personal injury deal were co-lead plaintiff counsel Scott Summy of Baron & Budd and Michael London. Their negotiations addressed legacy claims primarily relating to PFAS compounds — including PFOS and PFOA — that 3M voluntarily phased out beginning in 2000. 3M has stated that the settlement does not change its 2026 financial guidance or its 2027 financial framework, suggesting the company treated this liability as a manageable, ring-fenced obligation rather than an existential financial event.
What Still Has to Happen Before Money Flows
The AFFF lawsuit settlement 2026 agreement is signed, but claimants should not expect checks in the immediate future. Several procedural gates remain. The claimant-identification process under CMO 39 must conclude by November 13, 2026. The opt-in enrollment period will then open, during which eligible claimants — through their attorneys — must submit enrollment documentation and execute releases. After the enrollment window closes, 3M has 45 days to review participation numbers and decide whether to exercise its walk-away right based on the sealed participation thresholds. If 3M does not walk away, the final claimant list must be certified. Only after certification do the payment timelines activate, with the first substantial annual installments beginning in 2028. The reserve fund mechanism for future and unresolved claims adds another layer of administration that will unfold over years.
For claimants whose injuries intersect with pharmaceutical or medical device exposure in addition to AFFF — for instance, individuals who developed conditions that were then mistreated or misdiagnosed — there may be separate legal theories worth evaluating. A medical malpractice calculator can help individuals assess the potential value of claims arising from negligent medical treatment of AFFF-related conditions, independent of the mass tort settlement track. The two types of claims can sometimes proceed in parallel.
Frequently Asked Questions About the AFFF Lawsuit Settlement 2026
Who qualifies for the 3M AFFF personal injury settlement announced November 3, 2026?
To qualify for the AFFF lawsuit settlement 2026, a claimant must have one of six diagnosed conditions — kidney cancer, testicular cancer, liver cancer, thyroid cancer, thyroid disease, or ulcerative colitis — and must have had exposure to AFFF firefighting foam. Primary eligible groups include military veterans, military and civilian firefighters, airport workers, fire training site personnel, and individuals who consumed PFAS-contaminated drinking water near military bases or airports. Claimants must opt in and provide 3M a full release of all PFAS-related personal injury claims. Approximately 115,000 to 120,000 plaintiffs are estimated to be eligible.
What is the November 13, 2026 deadline and what happens if I miss it?
November 13, 2026 is the claimant-identification deadline established by Case Management Order 39 (CMO 39) in MDL 2873. By this date, eligible claimants must be formally identified to the court. Cases filed after this deadline require counsel to certify when the client was first retained, which may affect processing and positioning within the settlement distribution system. Missing this deadline does not necessarily bar a future claim — the enrollment measurement window runs until December 15, 2029 — but acting promptly is strongly advisable given state statutes of limitations, which typically run two to three years from diagnosis or discovery of the PFAS-related condition.
How is the $7.35 billion structured and when will claimants actually receive money?
The $7.35 billion nominal total has a present value of $5.8 billion, which 3M will record as a pre-tax charge in Q4 2026. A $50 million payment is scheduled for 2026, with no payments in 2027. The bulk of the fund — approximately $6.27 billion — is distributed in annual installments from 2028 through 2033 after participation thresholds are met and the final claimant list is certified. An additional $680 million reserve fund addresses remaining and future personal injury claims. Individual payment amounts depend on diagnosis category, exposure history, and the point-based allocation system that settlement administrators will apply.
Has DuPont settled the AFFF personal injury cases?
No. As of the November 3, 2026 announcement, DuPont has not reached a personal injury settlement in MDL 2873. DuPont reported approximately 13,700 personal injury cases pending in the MDL as of September 30, 2026 and is engaged in ongoing mediation. The 3M Master Settlement Agreement covers only 3M’s liability. DuPont claimants face a separate and unresolved litigation path. Additionally, the personal injury settlement is entirely distinct from the previously resolved public-water-system track (3M’s water-system deal received final approval March 29, 2024) and from MDL 3191 involving non-AFFF firefighter turnout gear, which is a different MDL with different defendants.
Can someone file a new AFFF lawsuit after November 13, 2026 and still participate in the settlement?
Yes, but with important caveats. The settlement enrollment measurement window remains open until December 15, 2029, so newly diagnosed individuals with qualifying conditions can potentially still participate. However, cases filed after November 13, 2026 are subject to CMO 39’s requirement that counsel certify the date of client retention, which signals heightened court scrutiny of late-filed claims. State statutes of limitations — generally two to three years from diagnosis or discovery of the PFAS-related condition — remain in effect and may independently bar claims filed too long after diagnosis. Unrepresented claimants should seek qualified legal counsel immediately to evaluate their eligibility window.
This content is provided for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction regarding the specific facts of your AFFF or PFAS-related personal injury claim.
Related reading: Negligent Nondisclosure In Medical Malpractice: How The Duty To Disclose Affects Your Settlement (2026)
Related reading: The Learned Intermediary Doctrine In Medical Malpractice: When Drug & Device Manufacturers — Not Doctors — Owe You A Warning (2026)
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.